MedTrace Logo

Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma

NCT03206866 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2017-07-02

No results posted yet for this study

Summary

Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets.

SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identified from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens \[4\]

Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative

Conditions

  • Role of Serum Regucalcin in Diagnosis of HCC

Interventions

DIAGNOSTIC_TEST

serum regucalcin antibody

serum regucalcin antibody

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-30
Primary Completion
2017-12-30
Completion
2017-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03206866 on ClinicalTrials.gov